WallStreetZenWallStreetZen

NASDAQ: BCAB
Bioatla Inc Stock Forecast, Predictions & Price Target

Analyst price target for BCAB

Based on 2 analysts offering 12 month price targets for Bioatla Inc.
Min Forecast
$7.00+102.31%
Avg Forecast
$9.50+174.57%
Max Forecast
$12.00+246.82%

Should I buy or sell BCAB stock?

Based on 2 analysts offering ratings for Bioatla Inc.
Buy
Strong Buy
0 analysts 0%
Buy
2 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their BCAB stock forecasts and price targets.

BCAB stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-03-27
lockedlocked$00.00+00.00%2023-12-05

1 of 1

Forecast return on equity

Is BCAB forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
37.5%

Forecast return on assets

Is BCAB forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

BCAB revenue forecast

What is BCAB's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$15.0M
Avg 2 year Forecast
$5.7M
Avg 3 year Forecast
$23.4M

BCAB vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
BCAB$3.46$9.50+174.57%Buy
KPTI$1.48$5.33+260.34%Strong Buy
NKTR$0.89$1.00+12.99%Hold
IVA$3.82$19.67+414.84%Strong Buy
GNLX$6.02$32.50+439.87%Buy

Bioatla Stock Forecast FAQ

Is Bioatla Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: BCAB) stock is to Buy BCAB stock.

Out of 2 analysts, 0 (0%) are recommending BCAB as a Strong Buy, 2 (100%) are recommending BCAB as a Buy, 0 (0%) are recommending BCAB as a Hold, 0 (0%) are recommending BCAB as a Sell, and 0 (0%) are recommending BCAB as a Strong Sell.

If you're new to stock investing, here's how to buy Bioatla stock.

What is BCAB's revenue growth forecast for 2024-2026?

(NASDAQ: BCAB) Bioatla's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.94%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.52%.

Bioatla's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast BCAB's revenue for 2024 to be $721,450,755, with the lowest BCAB revenue forecast at $721,450,755, and the highest BCAB revenue forecast at $721,450,755. On average, 1 Wall Street analysts forecast BCAB's revenue for 2025 to be $275,594,188, with the lowest BCAB revenue forecast at $275,594,188, and the highest BCAB revenue forecast at $275,594,188.

In 2026, BCAB is forecast to generate $1,123,058,342 in revenue, with the lowest revenue forecast at $1,123,058,342 and the highest revenue forecast at $1,123,058,342.

What is BCAB's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: BCAB) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is BCAB's Price Target?

According to 2 Wall Street analysts that have issued a 1 year BCAB price target, the average BCAB price target is $9.50, with the highest BCAB stock price forecast at $12.00 and the lowest BCAB stock price forecast at $7.00.

On average, Wall Street analysts predict that Bioatla's share price could reach $9.50 by Mar 27, 2025. The average Bioatla stock price prediction forecasts a potential upside of 174.57% from the current BCAB share price of $3.46.

What is BCAB's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: BCAB) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.